COVID-19-Related Outcomes in Primary Mitochondrial Diseases: An International Study
- PMID: 35190464
- PMCID: PMC8992603
- DOI: 10.1212/WNL.0000000000200240
COVID-19-Related Outcomes in Primary Mitochondrial Diseases: An International Study
Abstract
Background and objectives: To identify factors associated with severe coronavirus disease 2019 (COVID-19), defined by hospitalization status, in patients with primary mitochondrial diseases (PMDs), thereby enabling future risk stratification and informed management decisions.
Methods: We undertook a cross-sectional, international, registry-based study. Data were extracted from the International Neuromuscular COVID-19 Database and collected between May 1, 2020, and May 31, 2021. The database included subjects with (1) PMD diagnosis (any age), clinically/histopathologically suspected and/or genetically confirmed; and (2) COVID-19 diagnosis classified as "confirmed", "probable", or "suspected" based on World Health Organization definitions. The primary outcome was hospitalization because of COVID-19. We collected demographic information, smoking status, coexisting comorbidities, outcomes after COVID-19 infection, and PMD genotype-phenotype. Baseline status was assessed using the modified Rankin scale (mRS) and the Newcastle Mitochondrial Disease Adult Scale (NMDAS).
Results: Seventy-nine subjects with PMDs from 10 countries were included (mean age 41.5 ± 18 years): 25 (32%) were hospitalized, 48 (61%) recovered fully, 28 (35%) improved with sequelae, and 3 (4%) died. Statistically significant differences in hospitalization status were observed in baseline status, including the NMDAS score (p = 0.003) and mRS (p = 0.001), presence of respiratory dysfunction (p < 0.001), neurologic involvement (p = 0.003), and more than 4 comorbidities (p = 0.002). In multivariable analysis, respiratory dysfunction was independently associated with COVID-19 hospitalization (odds ratio, 7.66; 95% CI, 2-28; p = 0.002).
Discussion: Respiratory dysfunction is an independent risk factor for severe COVID-19 in PMDs while high disease burden and coexisting comorbidities contribute toward COVID-19-related hospitalization. These findings will enable risk stratification and informed management decisions for this vulnerable population.
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
References
-
- McFarland R, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol. 2010;9(8):829-840. - PubMed
-
- Get support if you’re clinically extremely vulnerable to coronavirus (COVID-19). GOV.UK. Accessed August 1, 2021. gov.uk/coronavirus-shielding-support.
-
- Interim Operational Considerations for Implementing the Shielding Approach to Prevent COVID-19 Infections in Humanitarian Settings. Centers for Disease Control and Prevention (CDC). Accessed August 1, 2021. cdc.gov/coronavirus/2019-ncov/global-covid-19/shielding-approach-humanit....
-
- World Health Organization. (2020). Coronavirus Disease 2019 (COVID-19): Situation Report, 61. World Health Organization; 2020. Accessed August 1, 2021. apps.who.int/iris/handle/10665/331605.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical